Together, our studies suggest that a combination therapy that targets both the PI3K/mTOR and the JAK/Stat pathways may reduce the frequency of treatment failures and decrease the risk of relapse in T-ALL patients. The gene discussed is PIK3CD; the disease is acute lymphoblastic leukemia.